These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35970431)

  • 1. A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1).
    Wirta DL; Senchyna M; Lewis AE; Evans DG; McLaurin EB; Ousler GW; Hollander DA
    Ocul Surf; 2022 Oct; 26():166-173. PubMed ID: 35970431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
    Tauber J; Berdy GJ; Wirta DL; Krösser S; Vittitow JL;
    Ophthalmology; 2023 May; 130(5):516-524. PubMed ID: 36574848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel TRPM8 agonist relieves dry eye discomfort.
    Yang JM; Li F; Liu Q; Rüedi M; Wei ET; Lentsman M; Lee HS; Choi W; Kim SJ; Yoon KC
    BMC Ophthalmol; 2017 Jun; 17(1):101. PubMed ID: 28651550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
    Clark D; Tauber J; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Sensitivity of Corneal TRPM8 Receptors to Menthol Instillation in Dry Eye Versus Normal Subjects.
    Corcoran P; Hollander DA; Ousler GW; Angjeli E; Rimmer D; Lane K; Abelson MB
    J Ocul Pharmacol Ther; 2017 Nov; 33(9):686-692. PubMed ID: 28933582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
    Evans D; Kenyon K; Ousler G; Watson M; Vollmer P; McLaurin EB; Torkildsen G; Winters J; Dodd J; Jordan R; Wills ST; Spana C
    J Ocul Pharmacol Ther; 2023 Nov; 39(9):600-610. PubMed ID: 37677000
    [No Abstract]   [Full Text] [Related]  

  • 10. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
    Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
    Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
    Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
    Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial.
    Pinto-Fraga J; López-Miguel A; González-García MJ; Fernández I; López-de-la-Rosa A; Enríquez-de-Salamanca A; Stern ME; Calonge M
    Ophthalmology; 2016 Jan; 123(1):141-53. PubMed ID: 26520171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Analysis of the Influence of Temperature and Humidity on Dry Eye Disease.
    Song MS; Lee Y; Paik HJ; Kim DH
    Korean J Ophthalmol; 2023 Dec; 37(6):501-509. PubMed ID: 37899282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.
    Sacchetti M; Lambiase A; Schmidl D; Schmetterer L; Ferrari M; Mantelli F; Allegretti M; Garhoefer G
    Br J Ophthalmol; 2020 Jan; 104(1):127-135. PubMed ID: 30944103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical cyclosporine A therapy for dry eye syndrome.
    de Paiva CS; Pflugfelder SC; Ng SM; Akpek EK
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD010051. PubMed ID: 31517988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Conditions Associated with Severity of Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management Study.
    Yu K; Bunya V; Maguire M; Asbell P; Ying GS;
    Ophthalmology; 2021 Oct; 128(10):1384-1392. PubMed ID: 33785415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.